| | | |

Phase 3 Clinical Trial to Test Durvalumab for Mesothelioma

ByAlex Strauss

phase 3 clinical trialA potential new first-line immunotherapy treatment for mesothelioma is now recruiting patients for a phase 3 clinical trial.

The trial will compare the immunotherapy drug durvalumab (IMFINZI) combined with chemotherapy against chemotherapy alone. 

Results from the phase 2 trials of this combination released last year were promising. Tests showed that it extended mesothelioma survival by about 8 months with no debilitating side effects. 

The randomized phase 3 clinical trial will try to confirm these results in a larger group of people.

Mesothelioma Treatment with Durvalumab

Durvalumab is an immune checkpoint inhibitor. Immune checkpoint inhibitors deactivate a cancer cell survival mechanism that helps cancer cells evade the immune system. Pleural mesothelioma and other types of cancer use proteins like PD-1 to protect themselves. 

Durvalumab and other immune checkpoint inhibitors (such as Keytruda) block PD-1. With their defenses down, cancer cells are more vulnerable to treatments like chemotherapy. 

The phase 3 clinical trial is especially relevant for people with unresectable mesothelioma. Right now, chemotherapy is the best hope for these patients. But chemotherapy is only marginally effective. If durvalumab helps it work better, even patients with inoperable mesothelioma might live longer. 

From Phase 2 to Phase 3 Clinical Trial

The earlier trials involved mesothelioma researchers in Australia, the US, and New Zealand. In the US, the study included 55 mesothelioma patients from 15 cancer centers. Researchers at Johns Hopkins led the research.

In the original study, mesothelioma patients got six treatments with Alimta, cisplatin and durvalumab. The treatments happened every three weeks. After three weeks, patients received just durvalumab for up to a year. It was the first study to show survival times longer than 20 months for patients with inoperable mesothelioma.

The phase 3 clinical trial is called DREAM3R. It will also take place in Australia, New Zealand, and the US. It will follow a similar protocol.

“We expect that the DREAM3R trial will be a particularly good treatment option for the 75% of MPM patients with epithelioid subtype, which is associated with significantly better outcomes from chemotherapy than the non-epithelioid subtype,” says lead US investigator Patrick Forde, MD, of Johns Hopkins University.

The phase 3 clinical trial aims to enroll 480 mesothelioma patients between 18 and 70. Patients must not have had any treatment yet and their cancer must not be removable surgically. 

Malignant mesothelioma affects more than 2,500 people in the US every year. Most of those people have the pleural type of mesothelioma which affects the lungs. If the new trial shows a clear benefit, durvalumab and chemotherapy could become a new first-line treatment for pleural mesothelioma. 

Sources: 

“Durvalumab immunotherapy proceeds to phase 3 trial for malignant pleural mesothelioma”, March 17, 2021, News Release PrECOG Research Group website, https://www.precogllc.org/news/durvalumab-immunotherapy-proceeds-to-phase-3-trial-for-malignant-pleural-mesothelioma

“Research Story Tip: Chemotherapy/Immunotherapy Combo Shows Promise for First-Line Treatment of Mesothelioma”, Johns Hopskins new release, June 11, 2020, https://www.hopkinsmedicine.org/news/newsroom/news-releases/research-story-tip-chemotherapyimmunotherapy-combo-shows-promise-for-first-line-treatment-of-mesothelioma

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    ByAlex Strauss

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…